Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.66 |
| ▸ | PRKACG | P22612 | 1/20 | 0.66 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.66 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.66 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938394 | 0.89 | PIK3CA (0.77) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL13781972 | 0.84 | PIK3CA (0.67) | PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL11938382 | 0.84 | PIK3CA (0.81) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL1911844 | 0.83 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL24023287 | 0.82 | PIK3CA (0.83) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL22600055 | 0.82 | PIK3CA (0.89) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL24023231 | 0.82 | PIK3CA (0.79) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL11938434 | 0.81 | PIK3CA (0.84) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL11938467 | 0.81 | PIK3CA (0.83) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL24023288 | 0.81 | PIK3CA (0.86) | PIK3CAPIK3CDPIK3CGPIK3CBGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8710085-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8476268-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010029082-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | PIK3CA 5/4885PIK3CD 3/4885PIK3CG 20/4885 |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | PIK3CA 5/4885PIK3CD 3/4885PIK3CG 20/4885 |
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CD 3/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.